Key result
WCD terminates sustained ventricular tachycardia in pediatric hypertrophic cardiomyopathy.
Why the study?
There is limited experience with wearable cardioverter-defibrillators in pediatric patients with hypertrophic cardiomyopathy and myocardial bridging.
Does a wearable cardioverter-defibrillator terminate life-threatening arrhythmias in a pediatric patient with hypertrophic cardiomyopathy and myocardial bridging?
Case Report (n=1)
Does a wearable cardioverter-defibrillator terminate life-threatening arrhythmias in a pediatric patient with hypertrophic cardiomyopathy and myocardial bridging?
Answers are grounded in this paper and cite their sources.
A wearable cardioverter-defibrillator can be successfully used as a bridge to ICD in pediatric high-risk patients with hypertrophic cardiomyopathy and myocardial bridging.
BACKGROUND: There is only limited experience with wearable cardioverter-defibrillators (WCD) in pediatric patients. We report on the successful application of a WCD in an adolescent patient with hypertrophic cardiomyopathy and myocardial bridging. CASE PRESENTATION: A 15-year-old girl presented with a history of recurrent syncope, dyspnea, and vertigo with exercise. Diagnostic work-up revealed non-obstructive hypertrophic cardiomyopathy and signs of myocardial ischemia with exercise. Given this high-risk constellation, the patient was scheduled for prophylactic implantation of an implantable cardioverter-defibrillator (ICD). One month after initial presentation and days prior to the planned ICD implantation, the patient collapsed during an episode of sustained ventricular tachycardia (VT) while running. VT was terminated by WCD shock delivery. Following this event, computerized tomography scan revealed myocardial bridging of the left anterior descending coronary artery causing a 90% stenosis in systole. After coronary surgery, life threatening arrhythmias have not recurred, but due to progressive heart failure, the patient underwent successful heart transplantation after 2 years. CONCLUSIONS: The reported case highlights the importance and applicability of WCDs and the potentially malign nature of myocardial bridging in pediatric high-risk patients.
No takes yet. Share an insight, caveat, or question.
Kurath‐Koller et al. (2020) conducted a case report in Hypertrophic cardiomyopathy and myocardial bridging (n=1). Wearable cardioverter-defibrillator (WCD) was evaluated on Termination of sustained ventricular tachycardia. A wearable cardioverter-defibrillator successfully detected and terminated a life-threatening episode of sustained ventricular tachycardia in a 15-year-old girl with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: